Investor Presentation H1 2023
130
Investor presentation
First six months of 2023
Rest of World at a glance
Diabetes trend in population
Diabetes market by value and
Novo Nordisk market share
Rest of World
Novo Nordisk reported sales
Million
21%
DKK
billion
300
250
80
18%
200
60
150
286
40
227
40
100
187
First half of 2023
Sales
(mDKK)
Growth²
Injectable GLP-13
4,046
39%
80%
RybelsusⓇ
1,371
161%
Total GLP-1
5,417
58%
35.3%1
GLP-1
Total insulin4
5,247
9%
60
60%
Other Diabetes care5
227
-27%
2.3%1
Insulin
Diabetes care
10,891
27%
40%
Obesity care
1,249
47%
5.4%1
20
50
20
20%
Diabetes & Obesity
12,140
29%
OAD
care
Rare disease7
2,041
-23%
0
2021
0
0%
2030
2045
May
2018
May
2023
Total
14,181
18%
Population with diabetes
Diabetes growth rate
GLP-1 MS
-Insulin MS
-OAD MS
Diabetes trend estimates based on the following International Diabetes Foundation
defined regions: South & Central America, Southeast Asia
Source: International Diabetes Federation: Diabetes Atlas 10th Edition 2021
1 CAGR calculated for last 5-year period
Competitor insulin value market shares, as of May 2023: Novo Nordisk 59%,
Others 41%; Competitor GLP-1 value market shares, as of May 2023: Novo Nordisk
79%, Others 21%. OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT,
May 2023 value figures
2 At constant exchange rates; ³ Comprises VictozaⓇ, Ozempic®;
4 Comprises TresibaⓇ, XultophyⓇ, Levemir®, NovoMix®, Ryzodeg®, NovoRapidⓇ
and FiaspⓇ5 Comprises Novo NormⓇ and needles; 6 Comprises SaxendaⓇ;
Comprises primarily Esperoct®, Refixia®, NovoSeven®, Novo Eight® and
NorditropinⓇView entire presentation